Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides
As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/21/6482 |
| _version_ | 1797512034416328704 |
|---|---|
| author | Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng |
| author_facet | Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng |
| author_sort | Shushan Ge |
| collection | DOAJ |
| description | As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect on cell proliferation, migration, invasion, and survival. As a result of the heterogeneity of BC, molecular imaging with HER2 probes can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors. This will provide a new approach for patients to choose treatment options and monitor treatment response. Furthermore, radionuclide molecular imaging has the potential of repetitive measurements, and it can help solve the problem of heterogeneous expression and conversion of HER2 status during disease progression or treatment. Different imaging probes of targeting proteins, such as monoclonal antibodies, antibody fragments, nanobodies, and affibodies, are currently in preclinical and clinical development. Moreover, in recent years, HER2-specific peptides have been widely developed for molecular imaging techniques for HER2-positive cancers. This article summarized different types of molecular probes targeting HER2 used in current clinical applications and the developmental trend of some HER2-specific peptides. |
| first_indexed | 2024-03-10T05:56:12Z |
| format | Article |
| id | doaj.art-ccab3b07725c4edb8ab11beaf61ca8a7 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T05:56:12Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-ccab3b07725c4edb8ab11beaf61ca8a72023-11-22T21:21:56ZengMDPI AGMolecules1420-30492021-10-012621648210.3390/molecules26216482Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small PeptidesShushan Ge0Jihui Li1Yu Yu2Zhengguo Chen3Yi Yang4Liqing Zhu5Shibiao Sang6Shengming Deng7Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaNuclear Medicine Laboratory of Mianyang Central Hospital, Mianyang 621099, ChinaDepartment of Nuclear Medicine, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou 215163, ChinaNuclear Medicine Laboratory of Mianyang Central Hospital, Mianyang 621099, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaAs the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect on cell proliferation, migration, invasion, and survival. As a result of the heterogeneity of BC, molecular imaging with HER2 probes can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors. This will provide a new approach for patients to choose treatment options and monitor treatment response. Furthermore, radionuclide molecular imaging has the potential of repetitive measurements, and it can help solve the problem of heterogeneous expression and conversion of HER2 status during disease progression or treatment. Different imaging probes of targeting proteins, such as monoclonal antibodies, antibody fragments, nanobodies, and affibodies, are currently in preclinical and clinical development. Moreover, in recent years, HER2-specific peptides have been widely developed for molecular imaging techniques for HER2-positive cancers. This article summarized different types of molecular probes targeting HER2 used in current clinical applications and the developmental trend of some HER2-specific peptides.https://www.mdpi.com/1420-3049/26/21/6482breast cancerHER2radionuclide molecular probesmolecular imagingclinical trials |
| spellingShingle | Shushan Ge Jihui Li Yu Yu Zhengguo Chen Yi Yang Liqing Zhu Shibiao Sang Shengming Deng Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides Molecules breast cancer HER2 radionuclide molecular probes molecular imaging clinical trials |
| title | Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides |
| title_full | Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides |
| title_fullStr | Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides |
| title_full_unstemmed | Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides |
| title_short | Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides |
| title_sort | review radionuclide molecular imaging targeting her2 in breast cancer with a focus on molecular probes into clinical trials and small peptides |
| topic | breast cancer HER2 radionuclide molecular probes molecular imaging clinical trials |
| url | https://www.mdpi.com/1420-3049/26/21/6482 |
| work_keys_str_mv | AT shushange reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT jihuili reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT yuyu reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT zhengguochen reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT yiyang reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT liqingzhu reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT shibiaosang reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides AT shengmingdeng reviewradionuclidemolecularimagingtargetingher2inbreastcancerwithafocusonmolecularprobesintoclinicaltrialsandsmallpeptides |